Arrowhead climbs on early Alzheimer's drug trial data
14/10/2026 13:01
BUZZ-Arrowhead climbs on early Alzheimer's drug trial data ** Shares of drugmaker Arrowhead Pharmaceuticals ARWR.O rise 6.7% to $62 premarket
** Co says its experimental Alzheimer's drug, ARO-MAPT, cut levels of disease-linked tau protein in spinal fluid by an average of 73% in healthy volunteers, with maximum reductions of 85%, in an early-to-mid-stage trial
** Abnormal buildups of tau protein are considered a key driver of Alzheimer's and other neurodegenerative brain disorders
** Protein reductions lasted for at least three months after the final dose, supporting the potential for quarterly dosing, co says
** Co is now testing the drug in early Alzheimer's patients, with data updates expected in 2027
** As of last close, stock down ~12% YTD
(Reporting by Kamal Choudhury in Bengaluru)
Recent news on Arrowhead Pharmaceuticals
See all newsBrief: Uk's MHRA Authorises Redemplo For Adults With Familial Chylomicronaemia Syndrome
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Brief: Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers